Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Deficit), Pre-Merger Financing (Details)

v3.21.2
Stockholders' Equity (Deficit), Pre-Merger Financing (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 03, 2021
shares
Jun. 29, 2020
USD ($)
shares
Apr. 30, 2021
shares
Jun. 30, 2021
USD ($)
$ / shares
shares
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
Director
$ / shares
shares
Jun. 30, 2020
USD ($)
Dec. 31, 2020
shares
Nov. 19, 2020
$ / shares
shares
Nov. 05, 2020
shares
Pre-Merger Financing [Abstract]                    
Common stock issued (in shares)       16,891,855   16,891,855   10,882,495    
Fair value change of warrant liability and premium conversion derivatives | $       $ 0 $ (919,000) $ (33,829,000) $ (721,000)      
Rexahn [Member]                    
Pre-Merger Financing [Abstract]                    
Warrants outstanding (in shares)       66,538   66,538       231,433
Securities Purchase Agreement [Member]                    
Pre-Merger Financing [Abstract]                    
Common stock issued (in shares)   1,249,996             3,749,992 3,749,992
Number of trading days           10 days        
Securities Purchase Agreement [Member] | Private Ocuphire [Member]                    
Pre-Merger Financing [Abstract]                    
Number of directors | Director           5        
Securities Purchase Agreement [Member] | Rexahn [Member]                    
Pre-Merger Financing [Abstract]                    
Number of directors | Director           1        
Securities Purchase Agreement [Member] | Investors [Member]                    
Pre-Merger Financing [Abstract]                    
Total investment | $   $ 21,150,000                
Securities Purchase Agreement [Member] | Directors [Member]                    
Pre-Merger Financing [Abstract]                    
Total investment | $   $ 300,000                
Series A Warrants [Member]                    
Pre-Merger Financing [Abstract]                    
Warrant issued (in shares)       5,665,838   5,665,838        
Exercise price (in dollars per share) | $ / shares                 $ 4.4795  
Exercisable term       5 years   5 years        
Warrants outstanding (in shares)       5,665,838   5,665,838        
Series A Warrants [Member] | Risk-Free Interest Rate [Member]                    
Pre-Merger Financing [Abstract]                    
Percentage of measurement input       0.004   0.004        
Series A Warrants [Member] | Expected Volatility [Member]                    
Pre-Merger Financing [Abstract]                    
Percentage of measurement input       0.866   0.866        
Series A Warrants [Member] | Expected Term [Member]                    
Pre-Merger Financing [Abstract]                    
Expected life           4 years 9 months 18 days        
Series A Warrants [Member] | Expected Dividend Yield [Member]                    
Pre-Merger Financing [Abstract]                    
Percentage of measurement input       0   0        
Series A Warrants [Member] | Waiver Agreements [Member]                    
Pre-Merger Financing [Abstract]                    
Fair value change of warrant liability and premium conversion derivatives | $           $ (33,800,000)        
Series B Warrants [Member]                    
Pre-Merger Financing [Abstract]                    
Warrant issued (in shares)       1,708,334   1,708,334        
Exercise price (in dollars per share) | $ / shares       $ 0.0001   $ 0.0001        
Number of shares issued, warrants exercised (in shares)     1,629,634              
Warrants outstanding (in shares)       78,700   78,700        
Series B Warrants [Member] | Waiver Agreements [Member]                    
Pre-Merger Financing [Abstract]                    
Aggregate number of shares (in shares) 1,708,334